These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 186874)

  • 1. [Treatment of Kahler's disease].
    Foa J; Carcassonne Y
    Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparative study of the melphalan and of the cyclophosphamide in the treatment of Kahler's disease].
    Bontoux D; Chenbit D; Delbarre F
    Therapeutique; 1971 Jan; 47(1):27-32. PubMed ID: 5572915
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].
    Bataille R; Morlock G; Rosenberg F; Sany J; Serre H
    Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent progress in chemotherapy of multiple myeloma].
    Tortarolo M; Cantore N; Russolillo S; Castaldo C; Buonanno G
    Recenti Prog Med; 1978 Jul; 65(1):44-68. PubMed ID: 370935
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
    Lee BJ; Sahakian G; Clarkson BD; Krakoff IH
    Cancer; 1974 Feb; 33(2):533-8. PubMed ID: 4812771
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)].
    Saporta L; Hugon C; Rondier J; Bontoux D; Delbarre F
    Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686
    [No Abstract]   [Full Text] [Related]  

  • 10. An overview of the status of the nitrosoureas in other tumors.
    Carter SK
    Cancer Chemother Rep 3; 1973 May; 4(3):35-46. PubMed ID: 4584034
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ophthalmoplegia revealing Kahler's disease].
    Ardouin M; Urvoy M; Eon JY; Le Blay R
    Bull Soc Ophtalmol Fr; 1978 Dec; 78(12):897-9. PubMed ID: 755570
    [No Abstract]   [Full Text] [Related]  

  • 13. [Chemotherapy of malignant skeletal tumors (author's transl)].
    Brunner KW; Wagner HP
    Ther Umsch; 1979 Jul; 36(7):653-6. PubMed ID: 89708
    [No Abstract]   [Full Text] [Related]  

  • 14. Proceedings: Treatment of multiple myeloma by a quadruple chemotherapy regime.
    Azam L; Delamore IW
    Br J Haematol; 1974 Jun; 27(2):362. PubMed ID: 4843684
    [No Abstract]   [Full Text] [Related]  

  • 15. Results and further perspectives of plasmocytoma chemotherapy.
    Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
    Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter: Treatment of myeloma.
    Jacobs P; Dubovsky D
    Br Med J; 1975 Mar; 1(5958):625. PubMed ID: 1125634
    [No Abstract]   [Full Text] [Related]  

  • 17. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 18. Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma.
    van Dijk JM; Sonnenblick M; Weissberg N; Rosin A
    Isr J Med Sci; 1986 Feb; 22(2):143-4. PubMed ID: 3753959
    [No Abstract]   [Full Text] [Related]  

  • 19. Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
    Strobel ES; Bauchmüller K; Schmitt-Gräff A; Engelhardt M
    Ann Hematol; 2005 Nov; 84(12):830-2. PubMed ID: 16132908
    [No Abstract]   [Full Text] [Related]  

  • 20. Alkeran and multiple myeloma.
    Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.